Enriched Aptamer Libraries Identified 100% of Patients with ER+/PR+/HER2- Lobular Carcinoma Breast Cancer in Pilot Study Presented at AACR 2017 Annual Meeting
IRVING, Texas, Apr. 3, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced results of a study that demonstrate the ability of the company’s ADAPT Biotargeting System™ to detect different molecular subtypes of breast cancer from a liquid biopsy collected from women with breast cancer. ADAPT Biotargeting System was used to develop libraries of aptamers using blood plasma exosomes to characterize system-wide changes associated with breast cancer subtypes. The study is presented today in a poster session at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C.
The ADAPT Biotargeting System uses a broad library of synthetically-manufactured molecules (aptamers) that bind to a wide range of biological targets, enabling them to profile biological samples at a systems-wide scale. Using ADAPT, the study showed that serial enrichment of individual plasma exosome samples promoted the evolution of aptamer libraries that dramatically improved the identification of different breast cancer subtypes. When enriched for detection of ER+/PR+/HER2- lobular carcinoma, the second most common type of breast cancer, the ADAPT Biotargeting System was able to identify 100% of independent cases within that subtype. The trained library also maintained the ability to detect other breast cancer subtypes with high accuracy (ROC AUC = 0.924).
“This study provides further validation of our unique ADAPT platform to accurately and correctly identify women with various types of breast cancer through a minimally-invasive liquid biopsy of circulating exosomes in the blood,” said David Spetzler, M.S., Ph.D., M.B.A., President and Chief Scientific Officer of Caris Life Sciences. “Our ADAPT technology is uniquely suited for profiling complex systems and phenotypes because it is based on ongoing evolution of aptamer libraries to continuously improve performance. In that sense, the library continues to mature over time with the addition of more and more clinical samples. More libraries for other breast cancer subtypes are currently being built.”
This data is a follow up study and continuation of the previously published data in Nature’s Scientific Reports (Scientific Reports 7, Article number: 42741 (2017) doi:10.1038/srep42741) on February 20, 2017, titled “Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach.”
Abstract 2754 / Poster 24: A novel liquid biopsy method for development of aptamer libraries that bind blood plasma exosomes from breast cancer patients
Summary: ADAPT was used to identify binding signatures in plasma exosomes that distinguish breast cancer patients from healthy controls.
Date: April 3, 2017
Time: 1:00 – 5:00 p.m. EDT
Location: Section 30
About Caris Life Sciences®
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s ADAPT Biotargeting System™ is a revolutionary and unbiased profiling platform currently being utilized for drug target identification, therapeutic discovery and development, fixed tissue-based companion diagnostics, blood-based cancer screening and biomarker identification. The ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state(s). Caris Molecular Intelligence®, the company’s Comprehensive Genomic Profiling Plus (CGP+) molecular testing service and the world’s leading immunotherapy diagnostic provider, assesses DNA, RNA and Proteins, including microsatellite instability (MSI), total mutational load (TML) and PD-L1, to reveal the molecular drivers of cancer and enable the delivery of personalized medicine. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international markets. To learn more, please visit www.CarisLifeSciences.com.
Caris Life Sciences Media Relations & Corporate Affairs